美國FDA將審查延長再生元製藥(REGN.US)Eylea方案治療糖尿病視網膜病變
格隆匯6月29日丨再生元製藥(REGN.US)週三説,美國FDA將審查該公司申請延長其暢銷眼科治療藥物Eylea間隔和劑量的申請。公司説,該申請包括對糖尿病視網膜病變患者每16周注射一次Eylea。糖尿病視網膜病變是美國勞動年齡成年人失明的主要原因。再生元製藥表示,如果獲得批准,延長方案將為Eylea提供更長的治療間隔和額外的劑量靈活性,Eylea在2019年獲得了FDA批准的4周和8周的劑量方案。再生元製藥去年稱Eylea在美國的銷售額接近58億美元,該公司表示,FDA將在2023年2月28日對這一16周的療程做出決定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.